What Your Pathology Report Tells You - in Plain English
When a biopsy comes back or your surgical specimen is analyzed, the result is a pathology report. It can look dense with abbreviations and numbers. Most of what you need to understand falls into four areas: tumor grade, hormone receptor status, HER2 status, and Ki67. These results help your clinical team decide which surgery is most suitable and whether you need treatment before or after surgery.
What Is in a Breast Cancer Pathology Report?
A pathologist - a specialist doctor who studies tissue under a microscope - examines a sample of your tumor and produces a written report. That report typically covers:
- The type of breast cancer (for example, invasive ductal carcinoma, invasive lobular carcinoma, or DCIS)
- Tumor grade - how different the cancer cells look from normal cells
- Hormone receptor status (ER and PR)
- HER2 status
- Ki67 index - a measure of how quickly cells are dividing
- Surgical margins - whether normal tissue surrounds the removed cancer
- Lymph node status, if nodes were biopsied or removed
Your oncologist and surgeon will use all of these findings together with tumor size and your preferences to plan the most suitable approach for you.
Tumor Grade: What Grade 1, 2, and 3 Mean
Grade describes how the cancer cells look compared to healthy breast cells. A lower grade means the cells look fairly normal. A higher grade means they look very different and divide more quickly.
UK pathologists use the Nottingham grading system, which scores three features of the tumor cells and adds the scores together to produce a final grade of 1, 2, or 3. The three features are:
- Tubule formation - how much of the tumor still forms tube-like structures, as healthy breast glands do
- Nuclear pleomorphism - how varied and irregular the cell nuclei look
- Mitotic count - how many cells are actively dividing at the time of the biopsy
Each feature receives a score of 1, 2, or 3. The total score ranges from 3 to 9:
- Grade 1 (score 3-5): Well-differentiated. Cells look close to normal. Tends to grow slowly.
- Grade 2 (score 6-7): Moderately differentiated. Cells show some abnormality. Growth rate is intermediate.
- Grade 3 (score 8-9): Poorly differentiated. Cells look very different from normal and divide quickly.
Grade is not the same as stage. Stage describes how far the cancer has spread. Grade describes how the cancer cells themselves look and behave. A stage 1 tumor can be grade 3. A stage 2 tumor can be grade 1. Your team looks at both when planning treatment.
Higher-grade tumors often prompt doctors to consider chemotherapy before or after surgery. The grade helps them decide whether to operate first or shrink the tumor with treatment before deciding on surgery.
Hormone Receptors: What ER-Positive and PR-Positive Mean
Estrogen receptor (ER) and progesterone receptor (PR) tests check whether your cancer cells carry receptors that respond to female hormones. If they do, estrogen and progesterone may be encouraging the cancer to grow.
About 7 in 10 breast cancers are ER-positive, according to Macmillan Cancer Support. ER-positive cancers often respond well to hormone-blocking therapies such as tamoxifen or aromatase inhibitors, which are daily tablets taken after surgery. These can reduce the risk of the cancer returning.
If your cancer is ER-positive and PR-positive, this is a favorable sign. These cancers tend to be slower-growing. In some cases, they may not need chemotherapy - though your team will always consider your full situation before deciding.
If your cancer is ER-negative, it will not respond to hormone-blocking treatment. Your surgical plan then depends more on HER2 status, grade, and chemotherapy response.
HER2 Status: Why It Matters for Your Surgery
HER2 (human epidermal growth factor receptor 2) is a protein on the surface of cells that helps them grow. In some breast cancers, the HER2 gene is amplified - meaning cells produce too much of this protein, causing faster growth. According to Macmillan Cancer Support, about 1 in 4 breast cancers has too many copies of the HER2 gene.
HER2-positive cancers tend to be higher grade. However, they respond to targeted therapies - most commonly trastuzumab (Herceptin) - that attach to the HER2 protein and block the cancer from growing. These targeted treatments have improved outcomes for many women with HER2-positive cancer.
A positive HER2 result does not mean you cannot have breast-conserving surgery. In many cases, doctors recommend starting with chemotherapy and targeted therapy before surgery - called neoadjuvant therapy. This approach can shrink the tumor before surgery, which may make a smaller operation possible than would otherwise be needed. Our guide to chemotherapy before robotic breast cancer surgery explains how this works in practice.
Ki67: The Proliferation Index
Ki67 is a protein found in cells that are actively dividing. Pathologists measure what percentage of cancer cells show Ki67 activity. A higher percentage suggests the cancer is growing quickly. A lower percentage suggests slower growth.
Many oncologists use a Ki67 index of around 20% as the threshold between low and high proliferation. Research indicates that high Ki67 values may be linked to better response to certain chemotherapy in some patients - because fast-dividing cells can be more vulnerable to chemotherapy. A high Ki67 value can sometimes mean faster response to chemotherapy.
Ki67 is always interpreted alongside grade, hormone receptor status, and HER2. If your report includes a Ki67 value and you are unsure what it means, ask your oncologist to explain it with your other results.
How Does Your Biomarker Profile Affect Your Surgery Options?
Your pathology results give your surgical team important information. They do not produce a single fixed plan - tumor size, breast size, lymph node status, and your preferences all matter too. But certain biomarker profiles do guide surgery discussions. The table below shows how those conversations typically go.
| Biomarker Profile | Typical Grade | Surgery Discussion Usually Covers | Additional Treatment Often Considered |
|---|---|---|---|
| ER/PR-positive, HER2-negative | Grade 1-2 | Lumpectomy often a strong option; mastectomy if tumor is large or multi-focal | Hormone therapy (tamoxifen or aromatase inhibitor) |
| ER/PR-positive, HER2-negative | Grade 3 | Lumpectomy or mastectomy; neoadjuvant chemotherapy may be discussed first | Chemotherapy plus hormone therapy |
| HER2-positive (any ER status) | Grade 2-3 | Targeted therapy to shrink tumor before surgery; lumpectomy may then become feasible | Trastuzumab (Herceptin) plus chemotherapy |
| Triple-negative (ER-, PR-, HER2-) | Grade 2-3 | Lumpectomy or mastectomy; chemotherapy often recommended before surgery | Chemotherapy; immunotherapy in some cases |
| DCIS (non-invasive) | Nuclear grade 1-3 | Wide local excision or mastectomy depending on extent and nuclear grade | Radiotherapy after lumpectomy; hormone therapy if ER-positive |
For illustrative guidance only. Sources: National Cancer Institute, Breast Cancer Treatment (PDQ); NIH, Variability in Breast Cancer Biomarker Assessment, PMC7963154.
As the table shows, breast-conserving surgery is an option for many biomarker profiles. The path to that conversation may differ - for HER2-positive or triple-negative cancers, chemotherapy before surgery may make conservation possible. Teams with robotic or minimally invasive experience may achieve clear margins with smaller operations than traditional surgery allows. Our article on what robotic breast surgery can and cannot do explains the practical differences.
Can Your Results Change After Surgery?
Sometimes, yes. A biopsy samples only a small part of the tumor. The full surgical specimen gives the pathologist much more tissue to examine. Occasional differences in findings - particularly for HER2 status or receptor scores - do occur. A study in the National Institutes of Health literature found differences between biopsy and surgical results in some cases. If your results change after surgery, your team will explain whether this affects plans for any additional therapy. Result changes after surgery are normal and help create a complete picture of your tumor.
Genomic Tests: When Standard Pathology Needs More Context
For some women - particularly those with ER-positive, HER2-negative, node-negative early-stage breast cancer - standard pathology may not clearly show whether chemotherapy is needed with hormone therapy. In these cases, your oncologist may recommend a genomic test.
Tests such as Oncotype DX and MammaPrint analyze patterns of gene activity in your tumor tissue. They can help predict how likely the cancer is to return and whether chemotherapy would help. They are not needed for every patient. They help most when standard results don't clearly show whether chemotherapy would benefit you.
If you have a family history of breast cancer or a known BRCA variant, your pathology results help guide decisions about genetic testing and risk-reducing surgery. Our guide to BRCA, genetic testing, and robotic breast surgery options covers this in more detail.
Getting a Second Opinion on Your Results
Pathology scoring - particularly for tumor grade and Ki67 - can vary slightly between pathologists and laboratories. If a surgical recommendation surprises you or doesn't feel right, asking for a second opinion is reasonable and common practice. Many women find that a second review either confirms the first plan or reveals other options.
If you are based in the UK and weighing your surgical options, you can arrange a review of your reports by Art of Healing Cancer, whose team works with UK patients considering minimally invasive and robotic breast surgery. A remote review before committing to a surgical plan can reveal alternative approaches worth exploring.
For more on why a second opinion matters when mastectomy has been recommended, see our guide to getting a second opinion on robotic surgery options. If you would like to discuss your pathology results privately and explore what minimally invasive surgery might look like for your case, you can submit an enquiry through BreastCancer.One's contact page.
Managing Anxiety While You Wait for Results
Waiting for a pathology report - or reading one for the first time - is one of the most stressful moments in a cancer diagnosis. Disrupted sleep and anxiety are normal at this stage. Ask your care team about options to help with sleep or stress. If you use any supplements while waiting for results, tell your oncologist or GP.
When to Talk to Your Doctor
Speak to your oncologist or breast surgeon if:
- You do not understand what any result in your pathology report means
- You have received a surgical recommendation and are unsure whether all options have been discussed with you
- Your receptor or HER2 results seem to differ between your biopsy report and your post-surgery report
- You want to know whether a genomic test such as Oncotype DX is appropriate for your situation
- You are considering a second opinion and want guidance on how to request one
This article is for general educational purposes and is not a substitute for personalized medical advice from a qualified oncologist. Always consult your oncologist or care team about your specific situation.